{"id":67234,"date":"2026-06-03T19:49:29","date_gmt":"2026-06-03T11:49:29","guid":{"rendered":"https:\/\/flcube.com\/?p=67234"},"modified":"2026-06-03T19:49:30","modified_gmt":"2026-06-03T11:49:30","slug":"kadwise-biotech-and-epiprobe-forge-strategic-partnership-to-advance-pediatric-cancer-diagnostics-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67234","title":{"rendered":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Wuhan Kadwise Biotechnology Co., Ltd.<\/strong>, a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a <strong>strategic partnership<\/strong> with <strong>Shanghai Epiprobe Biotechnology Co., Ltd.<\/strong>, the nation&#8217;s leader in pan-cancer early detection, to revolutionize <strong>pediatric cancer diagnostics<\/strong> through integrated molecular testing solutions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration combines Kadwise&#8217;s <strong>robust detection technology platforms<\/strong>, <strong>multiple approved early screening products<\/strong>, and <strong>extensive hospital network<\/strong> with Epiprobe&#8217;s <strong>highly sensitive liquid biopsy system<\/strong> for minimal residual disease (MRD) detection\u2014validated by <strong>tens of thousands of clinical cases<\/strong>\u2014to address critical gaps in pediatric oncology care across China.<\/p>\n\n\n\n<h2 id=\"h-partnership-structure-amp-strategic-alignment\" class=\"wp-block-heading\">Partnership Structure &amp; Strategic Alignment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Core Competency<\/th><th>Contribution to Partnership<\/th><\/tr><\/thead><tbody><tr><td><strong>Wuhan Kadwise Biotechnology<\/strong><\/td><td>Genetic molecular diagnostics, gynecologic oncology expertise<\/td><td>Detection technology platforms, approved screening products, top-tier hospital network<\/td><\/tr><tr><td><strong>Shanghai Epiprobe Biotechnology<\/strong><\/td><td>Pan-cancer early detection, liquid biopsy innovation<\/td><td>Highly sensitive MRD detection system, pediatric solid tumor\/hematologic malignancy expertise<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-focus-areas-amp-clinical-applications\" class=\"wp-block-heading\">Focus Areas &amp; Clinical Applications<\/h2>\n\n\n\n<h3 id=\"h-primary-collaboration-pillars\" class=\"wp-block-heading\">Primary Collaboration Pillars<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Screening for Pediatric Malignancies<\/strong>: Development of comprehensive screening protocols for childhood cancers<\/li>\n\n\n\n<li><strong>Minimal Residual Disease (MRD) Detection<\/strong>: Advanced liquid biopsy monitoring for treatment response and relapse prediction<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-impact-objectives\" class=\"wp-block-heading\">Clinical Impact Objectives<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Diagnostics<\/strong>: Enhanced accuracy and reliability of pediatric tumor molecular testing<\/li>\n\n\n\n<li><strong>Standardization<\/strong>: Establishment of uniform diagnostic protocols across Chinese healthcare institutions<\/li>\n\n\n\n<li><strong>Clinical Translation<\/strong>: Accelerated implementation of innovative technologies into routine pediatric oncology practice<\/li>\n\n\n\n<li><strong>Quality Improvement<\/strong>: Upgrading precision diagnosis and treatment standards for pediatric cancers nationwide<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-technology-integration-amp-innovation-framework\" class=\"wp-block-heading\">Technology Integration &amp; Innovation Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Real-World Clinical Needs<\/strong>: Solutions grounded in actual pediatric oncology challenges rather than theoretical applications<\/li>\n\n\n\n<li><strong>Complementary Platforms<\/strong>: Integration of Kadwise&#8217;s genetic diagnostics with Epiprobe&#8217;s liquid biopsy capabilities<\/li>\n\n\n\n<li><strong>Validation Scale<\/strong>: Leverages Epiprobe&#8217;s tens of thousands of validated clinical cases for robust performance data<\/li>\n\n\n\n<li><strong>Hospital Network Access<\/strong>: Utilizes Kadwise&#8217;s collaborative relationships with top-tier Chinese hospitals for rapid adoption<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong>: Builds upon Kadwise&#8217;s existing portfolio of approved diagnostic products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-strategic-implications\" class=\"wp-block-heading\">Market Opportunity &amp; Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-pediatric-oncology-landscape-in-china\" class=\"wp-block-heading\">Pediatric Oncology Landscape in China<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Diagnostic Needs<\/strong>: Limited specialized molecular diagnostics for childhood cancers<\/li>\n\n\n\n<li><strong>Early Detection Gap<\/strong>: Critical need for improved screening tools to enable earlier intervention<\/li>\n\n\n\n<li><strong>MRD Monitoring Deficiency<\/strong>: Inadequate tools for post-treatment monitoring and relapse prediction<\/li>\n\n\n\n<li><strong>Standardization Challenge<\/strong>: Fragmented diagnostic approaches across different healthcare institutions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-advantages\" class=\"wp-block-heading\">Competitive Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Position<\/strong>: Comprehensive pediatric-focused molecular diagnostics partnership in China<\/li>\n\n\n\n<li><strong>Integrated Solution<\/strong>: Unique combination of screening and monitoring capabilities in single framework<\/li>\n\n\n\n<li><strong>Clinical Validation<\/strong>: Extensive real-world data supporting technology performance claims<\/li>\n\n\n\n<li><strong>Healthcare System Integration<\/strong>: Direct access to leading pediatric oncology centers through hospital networks<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-benefits-for-partner-companies\" class=\"wp-block-heading\">Strategic Benefits for Partner Companies<\/h2>\n\n\n\n<h3 id=\"h-for-kadwise-biotechnology\" class=\"wp-block-heading\">For Kadwise Biotechnology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong>: Entry into high-growth pediatric oncology diagnostics segment<\/li>\n\n\n\n<li><strong>Technology Enhancement<\/strong>: Augmentation of existing platforms with cutting-edge liquid biopsy capabilities<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: New commercial opportunities beyond gynecologic oncology focus<\/li>\n\n\n\n<li><strong>Innovation Leadership<\/strong>: Positioning as pioneer in integrated pediatric cancer diagnostics<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-epiprobe-biotechnology\" class=\"wp-block-heading\">For Epiprobe Biotechnology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Scale<\/strong>: Access to Kadwise&#8217;s established hospital network and commercial infrastructure<\/li>\n\n\n\n<li><strong>Product Validation<\/strong>: Enhanced credibility through integration with approved diagnostic products<\/li>\n\n\n\n<li><strong>Market Penetration<\/strong>: Accelerated adoption of MRD detection system in pediatric oncology settings<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong>: Strengthened leadership in China&#8217;s precision oncology diagnostics market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-implementation-timeline-amp-expected-outcomes\" class=\"wp-block-heading\">Implementation Timeline &amp; Expected Outcomes<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase 1<\/strong>: Technology integration and protocol development (6-12 months)<\/li>\n\n\n\n<li><strong>Phase 2<\/strong>: Clinical validation studies across partner hospital network (12-24 months)<\/li>\n\n\n\n<li><strong>Phase 3<\/strong>: Regulatory submissions and commercial launch (24-36 months)<\/li>\n\n\n\n<li><strong>Long-term Vision<\/strong>: National standard for pediatric cancer molecular diagnostics in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-broader-healthcare-impact\" class=\"wp-block-heading\">Broader Healthcare Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Outcomes<\/strong>: Earlier detection and more precise monitoring expected to improve survival rates<\/li>\n\n\n\n<li><strong>Healthcare Efficiency<\/strong>: Standardized protocols reduce diagnostic variability and unnecessary procedures<\/li>\n\n\n\n<li><strong>Economic Benefits<\/strong>: Earlier intervention and better monitoring may reduce long-term treatment costs<\/li>\n\n\n\n<li><strong>Global Relevance<\/strong>: Success in China&#8217;s large pediatric population could inform international approaches<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation, technology development, and market impact. Actual results may differ due to regulatory requirements, clinical validation outcomes, and market adoption factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,3461,3247],"class_list":["post-67234","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-epiprobe-biotechnology","tag-kadwise-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation&#039;s leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67234\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China\" \/>\n<meta property=\"og:description\" content=\"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation&#039;s leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67234\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T11:49:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T11:49:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China\",\"datePublished\":\"2026-06-03T11:49:29+00:00\",\"dateModified\":\"2026-06-03T11:49:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234\"},\"wordCount\":639,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0302.webp\",\"keywords\":[\"Cancer\",\"Epiprobe Biotechnology\",\"Kadwise Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67234#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67234\",\"name\":\"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0302.webp\",\"datePublished\":\"2026-06-03T11:49:29+00:00\",\"dateModified\":\"2026-06-03T11:49:30+00:00\",\"description\":\"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation's leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67234\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67234#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China - Insight, China&#039;s Pharmaceutical Industry","description":"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation's leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67234","og_locale":"en_US","og_type":"article","og_title":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China","og_description":"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation's leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.","og_url":"https:\/\/flcube.com\/?p=67234","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T11:49:29+00:00","article_modified_time":"2026-06-03T11:49:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67234#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67234"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China","datePublished":"2026-06-03T11:49:29+00:00","dateModified":"2026-06-03T11:49:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67234"},"wordCount":639,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67234#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","keywords":["Cancer","Epiprobe Biotechnology","Kadwise Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67234#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67234","url":"https:\/\/flcube.com\/?p=67234","name":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67234#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67234#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","datePublished":"2026-06-03T11:49:29+00:00","dateModified":"2026-06-03T11:49:30+00:00","description":"Wuhan Kadwise Biotechnology Co., Ltd., a China-based gynecologic oncology specialist with extensive expertise in genetic molecular diagnostics, has announced a strategic partnership with Shanghai Epiprobe Biotechnology Co., Ltd., the nation's leader in pan-cancer early detection, to revolutionize pediatric cancer diagnostics through integrated molecular testing solutions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67234#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67234"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67234#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","width":1080,"height":608,"caption":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67234#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kadwise Biotech and Epiprobe Forge Strategic Partnership to Advance Pediatric Cancer Diagnostics in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67234"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67234\/revisions"}],"predecessor-version":[{"id":67236,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67234\/revisions\/67236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67235"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}